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Introduction: Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic intersti-
tial pneumonias. It is a serious and progressive lung disease with a median survival of three
years. The role of comorbidities in the prognosis of IPF is not clear.
Objectives: To describe comorbidity and co-medication in a Danish IPF cohort and the associ-
ation between clinically important comorbidities and survival.
Methods: The study cohort included all patients diagnosed with IPF at Aarhus University Hos-
pital, Denmark between April 2003 and April 2009. Details on diagnostic examinations, pulmo-
nary function, medication and comorbidities were registered based on medical records.
Results: A total of 121 patients were included. The most frequently observed comorbidities
were cardiovascular disease (20%), arterial hypertension (15%) and diabetes mellitus (11%).
Cardiovascular disease diagnosed during follow-up significantly increased mortality (HR 4.7,
95% CI 2.0e11.1). No difference was found based on cardiovascular disease already present
at the time of IPF diagnosis. Diabetes (HR 2.5, 95% CI 1.04e5.9) and anticoagulant treatment
(HR 3.3, 95% CI 1.5e7.2) were also factors associated with a significantly higher mortality in
this population-based cohort.
Conclusion: These findings emphasize the need of careful diagnosis and treatment of comor-
bidities and their risk factors in patients with IPF. In the absence of efficient treatment options
for the majority of patients diagnosed with IPF, this may play a role in the effort to optimize
the survival of IPF patients. Further studies are needed to fully clarify the impact of comorbid-
ities on prognosis in patients diagnosed with IPF.
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Idiopathic pulmonary fibrosis (IPF) is the most common of
the idiopathic interstitial pneumonias. It is a serious and
progressive disease with a median survival of 2e3 years. In
many cases, IPF is not diagnosed until pulmonary function is
severely impaired. Comorbid diseases like lung cancer and
cardiovascular disease may affect the prognosis of patients
with IPF. However, the reported prevalence of comorbidity
is variable and little is known about the impact of
concomitant diseases on survival in patients with IPF.
Corticosteroid therapy was widely used in IPF until
recently, and may have had a negative influence on some
comorbid diseases such as diabetes and osteoporosis. The
aim of this study was to describe important comorbid
conditions and to assess their impact on outcome in a well-
characterized cohort of Danish IPF patients.Methods
Study patients
IPF patients were identified in the Interstitial Lung Disease
(ILD) Registry at Aarhus University Hospital, a retrospective
cohort including all incident patients diagnosed with ILD at
the Department of Respiratory Diseases, Aarhus University
Hospital, between 1 April 2003 and 1 April 2009. ILD di-
agnoses in the International Classification of Diseases,
version 10 (ICD-10) and lists of HRCT scans performed at the
hospital were used to identify ILD patients in the hospital’s
administration system. All ILD diagnoses were re-evaluated
according to standard diagnostic criteria by two ILD
specialist pulmonologists. All available HRCT scans were re-
evaluated by expert thoracic radiologists, and all biopsies
had been evaluated by expert pathologists at our institution
[1].
IPF was diagnosed according to the 2011 ATS/ERS/JRS/
ALAT criteria [2]. Eligible patients were followed from the
time of first hospital visit with suspected ILD to the last
visit, death or transplantation. Follow-up ended 15
November 2009.
The study was approved by the Danish Data Protection
Agency and The Danish National Board of Health.
Data collection and assessments
All comorbidities were registered based on information
from medical records. A diagnosis of diabetes was regis-
tered if the patient received antidiabetic therapy. Osteo-
porosis was registered in the presence of a DXA-scan with T-
score below 2.5 or a history of fragility fracture. Cardio-
vascular disease was defined as one or more of the
following: ischaemic heart disease, cerebral infarction or
peripheral arterial disease based on patients’ medical
records.
Pulmonary hypertension (PH) was diagnosed in the
presence of a tricuspid pressure regurgitation gradient
40 mmHg, a tricuspid annular plane systolic excursion
<1.8 cm or right ventricular dilatation on echocardiography
and/or mean pulmonary artery pressure 25 mmHg on rightheart catheterization (RHC). Mild PH was defined as
tricuspid regurgitation gradient 60 mmHg or mean pul-
monary artery pressure 35 mmHg, and severe PH was
defined as tricuspid regurgitation gradient >60 mmHg or
mean pulmonary artery pressure >35 mmHg. PH was
considered present at the time of diagnosis when the
diagnosis was made within 90 days of the first visit to the
department. When PH was diagnosed later than 90 days
after first visit to the department it was considered as
diagnosed during follow-up. Echocardiography was used as
a screening tool for PH prior to referral for RHC.
Treatment for comorbid conditions was registered when
the patient received the treatment at any time during the
study period.
Severity of IPF was assessed on the basis of the GAP
prognostic model [3] that incorporates gender, age, diffu-
sion capacity of carbon monoxide (DLco) and forced vital
capacity (FVC), and allows a separation of patients into
disease categories with significantly different prognosis.
Causes of death were registered based on the information
from medical records. Follow-up with respect to mortality
was based on information from the hospital’s currently
updated patient administration system and was complete.
Statistical analysis
Data are presented as means  SD if continuous or as fre-
quencies if categorical. Unless otherwise specified, the
number of patients with available data (n) was used in the
calculation of summary statistics. Survival was evaluated
using the KaplaneMeier method, and the log-rank test was
used to determine statistical significance. Differences in
hazard ratio (HR) for death were evaluated using Cox pro-
portional hazards analysis. Unadjusted and adjusted Cox
proportional hazards regression analyses were performed,
and HR are presented along with 95% confidence intervals.
Comorbidities diagnosed during follow-up were assessed as
time dependent covariates.
Adjustment was performed using age and FVC as
continuous variables and gender as categorical variable.
Based on the number of events in the survival analysis, the
number of variables in the adjusted analysis had to be
limited to the clinically most important and robust pa-
rameters, but the inclusion of DLco in the model did not
change the results. Differences in the use of antidepres-
sants were assessed using a logistic regression model. All
analyses were performed using STATA statistical software
(version 12.1; StataCorp, College Station, Texas, USA).
Results
Comorbid conditions in IPF
A total of 121 IPF patients were included. IPF was the most
frequent diagnosis in the 2003e2009 ILD cohort and
constituted 28% of the diagnoses. Ninety-seven patients
were diagnosed with definite IPF and one patient with
possible IPF. Furthermore, 23 patients were classified as
having IPF based on a probable UIP pattern on HRCT and
clinical features typical of IPF, although no histopatholog-
ical diagnosis was made because a surgical lung biopsy
Table 2 Comorbid diseases in the Danish IPF cohort.
Comorbid diagnosis At time of
inclusion
n (%)
Diagnosed
during
follow-up
n (%)
Total
n (%)
Cardiovascular diseasea 24 (20%) 9 (7%) 33 (27%)
Arterial hypertension 18 (15%) 4 (3%) 22 (18%)
Ischaemic heart disease 16 (13%) 6 (5%) 22 (18%)
Pulmonary hypertension 12 (10%) 14 (11%) 26 (21%)
Diabetes 11 (9%) 10 (8%) 21 (17%)
Gastro-oesophageal
reflux
10 (8%) 0 10 (8%)
Depression 8 (7%) 20 (17%) 25 (21%)
Osteoporosis 8 (7%) 10 (8%) 18 (15%)
Cerebral infarction 8 (7%) 3 (2%) 11 (9%)
Atrial fibrillation 5 (4%) 6 (5%) 11 (9%)
Lung cancer 0 7 (6%) 7 (6%)
Other cancersb 0 4 (3%) 4 (3%)
a Ischaemic heart disease, cerebral infarction, peripheral
arteriosclerosis. Some patients had more than one diagnosis.
b Bladder (n Z 1), rectum (n Z 1), prostate (n Z 2).
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months (SD Z 19.2). One-year survival was 73% and 5-year
survival was 34%. Smoking was not associated with poorer
survival (HR p Z 0.19). Demographics and clinical charac-
teristics are shown in Table 1.
Sixty-one deaths occurred during the study period.
Forty-one patients were still under follow-up at our insti-
tution at the end of the study period, while 15 patients had
been discharged for further follow-up at their local hospi-
tals. Four patients underwent a lung transplant.
The most frequent comorbidities among IPF patients are
listed in Table 2. Osteoporosis was diagnosed in ten patients
(8%) during follow-up; eight of these patients had received
steroid therapy during follow-up. Antidepressant therapy,
either selective serotonin re-uptake inhibitors or tricyclic
antidepressants, was used by a total of 25 patients (21%). At
the time of IPF diagnosis, only eight of them had a diagnosis
of depression and received antidepressant therapy. No
difference in the frequency of antidepressant therapy was
observed in patients with mild, moderate or severe IPF;
with severity assessment based on the GAP staging system
[3].
Lung cancer was diagnosed in seven patients (6%). The
follow-up time was 197 person-years, equivalent to an
incidence rate of 3.6%/year. The incidence of lung cancer
in the general Danish population was 83/100,000/year for
men (0.083%/year) and 64/100,000/year for women
(0.064%/year) in 2010 [4]. A review of medical records of
the patients alive at the end of follow-up, revealed no
additional lung cancer cases up to January 2013. No dif-
ference in survival from the time of IPF diagnosis was seen
between lung cancer patients and patients without lung
cancer. Survival from the cancer diagnosis ranged from one
to fifteen months. The available data on cancer stage and
therapy were incomplete, but none of the patients under-
went surgical therapy or other intendedly curative therapy.
The presence of diabetes at inclusion was associated
with a statistically significant decrease in survival (Fig. 1).
The difference persisted after adjustment for age, gender
and FVC (HR 2.47, 95% CI 1.04e5.88, pZ 0.041). Seven out
of nine deaths in diabetic IPF patients were fibrosis-
related, one was cancer-related and one was of unknown
cause. The percentage of fibrosis-related deaths was the
same among diabetics and non-diabetics. DiabetesTable 1 Demographics and clinical characteristics in the
Danish IPF cohort.
n 121
Male:female 93:28
% male 77
Age (SD) 67.4 (8.4)
Smoking % (current or previous) 81
Number of pack years 29
Clinical-radiological diagnosis % 57
Histological diagnosis % 43
FVC % predicted (SD) 72.0 (20.7)
DLCO % predicted (SD) 42.3 (16.4)
FVC: forced vital capacity, DLCO: diffusion capacity of carbon
monoxide.diagnosed during follow-up did not affect survival (Tables 3
and 4). All patients with diabetes diagnosed during follow-
up (n Z 10) received corticosteroid therapy. Of the pa-
tients who had diabetes at the time of IPF diagnosis, eight
out of eleven patients (73%) received corticosteroids.
No survival difference was seen based on the presence of
cardiovascular disease prior to IPF diagnosis, p Z 0.17
(crude) and p Z 0.27 (adjusted for age, gender and FVC),
but cardiovascular disease diagnosed during the follow-up
period significantly increased mortality (HR 4.7, 95% CI
2.0; 11.1, p < 0.001). Four patients died of their lung dis-
ease, two patients died of combined pulmonary and cardiac
cause. One death was caused by intracerebral haemorrhage
and one was of unknown cause. One patient was still alive
at the end of the follow-up period.
Half of the patients (61/121) received medical therapy
for gastro-oesophageal reflux, either because of symp-
tomatic gastro-oesophageal reflux or prophylacticallyFigure 1 Survival time estimates based on presence or
absence of diabetes. HR Z 3.1, p Z 0.002 (unadjusted).
Table 3 Therapy given for IPF 2003e2009.
n %
Prednisolone 91 75
High-dose methylprednisolone courses 64 53
Both Prednisolone and high-dose
methylprednisolone courses
52 43
Azathioprine 75 62
N-acetylcysteinea 69 57
Triple therapyb 58 48
Cyclophosphamide 8 7
Oxygen therapy 67 55
a N-acetylcysteine (NAC) was only used as part of combination
therapy, none of the patients received NAC alone.
b N-acetylcysteine, prednisolone, azathioprine.
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ence in survival was seen between the treated and non-
treated groups (p Z 0.74). Symptomatic gastro-oesopha-
geal reflux did not impact on survival (HR 1.6, 95% CI (0.60;
4.4)) (Table 3).
IPF therapy
The treatment options used in IPF at the time of the study
are listed in Table 5. Comparison of treated and untreated
groups in adjusted analysis revealed no significant positive
or negative influence on survival (data not shown).
Anticoagulant therapy
Sixteen patients received anticoagulant treatment with
either warfarin (n Z 15) or phenprocoumon (n Z 1). Clin-
ical indications for anticoagulant treatment were deep
venous thrombosis (n Z 3), pulmonary embolism (n Z 4),
artificial heart valve (n Z 2), atrial fibrillation (n Z 3),
transitory cerebral ischaemia (n Z 1), and pulmonary hy-
pertension (n Z 3). A pronounced statistically significant
survival difference was seen in favour of the non-treated
group (p < 0.001) (Fig. 2). The difference persisted after
adjustment for age, gender and FVC (HR 3.3, 95% CI
1.55e7.21, p Z 0.002).
The results were unchanged when we excluded three
patients receiving anticoagulants due to PH (adjusted HR
3.49, 95% CI 1.56e7.81, p Z 0.002).Table 4 Comorbidity present at first hospital visit for IPF
and its association to survival (adjusted for age, gender and
FVC).
n HR (95% CI) p
Cardiovascular disease 24 0.66 (0.32; 1.37) 0.27
Diabetes 11 2.5 (1.04; 5.9) 0.041
Pulmonary hypertension 12 2.2 (0.94; 5.2) 0.068
Gastro-oesophageal reflux 10 1.6 (0.60; 4.4) 0.34
GER medication 61 1.0 (0.58; 1.8) 0.95
Anticoagulant treatment
(Non-PH indication)
13 3.3 (1.5; 7.2) 0.002
GER: gastro-oesophageal reflux, PH: pulmonary hypertension.Pulmonary hypertension
A total of 26 patients were diagnosed with PH. In 12 pa-
tients (10%), the lung disease was complicated by PH at the
time of IPF diagnosis, seven patients had mild PH and five
had severe PH. In these patients with PH, unadjusted
mortality was significantly higher than in patients without
pulmonary hypertension (pZ 0.048), but the difference did
not persist after adjustment for age, gender and FVC (HR
2.2, 95% CI 0.94e5.2, p Z 0.068). During follow-up, 14
additional patients were diagnosed with PH, twelve of
those had mild PH and two patients had severe PH. The
development of PH caused no difference in survival when
compared to non-PH patients in the cohort.
In eight patients, PH was diagnosed based on RHC and in
18 patients, the primary diagnosis was based on echocar-
diography. Four of those patients had RHC performed later
in the course of disease. Three patients had severe PH
(mPAP >35 mmHg) at the time of IPF diagnosis, and one
patient diagnosed during follow-up had severe PH. Two
patients were diagnosed with severe PH based on echo-
cardiography (tricuspid regurgitation gradient >60 mmHg).
Twenty-three patients with PH (88%) required long-term
oxygen treatment, and six patients (23%) received medical
therapy for out-of-proportion PH. Survival range in out-of
proportion PH was 4 months to 2.4 years.
Discussion
Main results
The most frequently observed comorbidities were cardio-
vascular disease (20%), arterial hypertension (15%) and
diabetes mellitus (11%). Cardiovascular disease diagnosed
during follow-up significantly increased mortality (HR 4.7,
95% CI 2.0e11.1). No difference was found based on car-
diovascular disease already present at the time of IPF
diagnosis. Diabetes (HR 2.5, 95% CI 1.04e5.9) and antico-
agulant treatment (HR 3.3, 95% CI 1.5e7.2) were also fac-
tors associated with a significantly higher mortality in this
population-based cohort.
The impact of comorbidity on survival in IPF is not well
characterized, and studies are few. This study describes the
frequency of comorbidities in a Danish IPF cohort with
typical demographic and clinical characteristics. Preva-
lence data on comorbidity in IPF are sparse. In a large
cohort of American IPF patients identified from medical
claims databases, 25% of the patients were diabetics and
25% had coronary artery disease [5]. In a small, population-
based cohort from Minnesota, USA that included 47 patients
with IPF [6], coronary artery disease was present in 45% of
patients, diabetes in 17% and depression in 11%. The Min-
nesota patients’ higher age, higher DLCO and longer sur-
vival may explain the higher frequency of comorbidities
compared to our cohort. BMI and smoking status were
comparable between the two cohorts. To our knowledge,
this is the only study of comorbidity in a comparable cohort
that has been published.
Diabetes was a significant prognostic determinant in the
present study. A higher prevalence of diabetes in IPF pa-
tients compared with the background population has
Table 5 Comorbidity diagnosed during IPF follow-up and its association to survival (adjusted for age, gender and FVC).
n Mean follow-up time to
comorbid diagnosis Days (range)
HR (95% CI) p
Cardiovascular disease 9 516 (118; 986) 4.7 (2.0; 11.1) <0.001
Diabetes 10 597 (78; 1464) 1.1 (0.33; 3,8) 0.85
Pulmonary hypertension 14 620 (192; 1213) 2.2 (0.82; 6.0) 0.12
Comorbidity influence survival in IPF 651previously been reported [7,8], but to our knowledge, the
survival implication of diabetes in IPF has not previously
been addressed. There is no evidence that corticosteroid
therapy modifies the natural history of the disease, and
recommendations against its use are strong [2,9]. We have
no data to assess the degree of diabetes control or
compliance to antidiabetic therapy in this cohort. The
reasons for the observed difference in survival are not
clear, but poor diabetes control due to steroid treatment is
likely to have played a role. The change in treatment rec-
ommendations for IPF may in itself improve outcome in
diabetic IPD patients, but the possible impact of diabetes
on prognosis in IPF remains an important focus for further
investigations in larger IPF cohorts.
Cardiovascular disease diagnosed during the course of
IPF resulted in a highly significant decrease in survival. On
the other hand, cardiovascular disease already present at
the time of IPF diagnosis, did not impact on survival. A
British caseecontrol study showed that ischaemic heart
disease was four times more frequent in IPF patients than in
age- and gender-matched controls [10], but the study did
not assess survival implications in IPF. Cardiovascular dis-
ease was also investigated as one of several potential
predictors of mortality in a prognostic model developed in a
large IPF cohort from two clinical trials [11]. Similar to our
study, cardiovascular disease was present at baseline in 27%
of the patients, and no significant difference in all-cause
mortality was found based on the presence of cardiovas-
cular disease. These results based on a large group of
participants in a clinical trial corroborate our findings in a
cohort of unselected patients in a population-based study.
It contrasts with findings in COPD where cardiovascular
disease is known to be an important prognostic factorFigure 2 Survival time estimates based on anticoagulant
treatment. HR Z 3.4, p < 0.001 (unadjusted).[12,13]. However, Nathan et al. [14] showed that a sub-
group of IPF patients who were transplant candidates had a
higher prevalence of coronary artery disease than trans-
plant candidates with COPD, and found that mortality was
significantly higher among IPF patients.
The occurrence of lung cancer is low in the Danish IPF
cohort compared with previous studies. Ozawa et al. [15]
reported a lung cancer incidence of 20% in a Japanese
cohort. Earlier IPF diagnosis and longer observation time
owing to long survival seemed to account for the difference
in the occurrence of lung cancer between the Japanese and
the Danish cohort. In another Japanese study, 17% (9/52) of
IPF deaths were ascribed to lung cancer [16], and in the
Minnesota cohort [6], 17% (8/47) of the patients developed
lung cancer.
A large, population-based study from Britain [17]
compared IPF patients with age- and gender-matched
controls, and found a lung cancer rate of 122 per
10,000 person-years among IPF patients and 22.9 per
10,000 person-years among controls. The rate of 3.6% per
year found in our study was three times higher than in the
British study. In another British study, Harris et al. [18]
showed that lung cancer caused 9% of deaths in patients
with CFA/IPF. Different methods and study populations
complicates a direct comparison, but our results corrobo-
rate other studies showing a considerably increased risk of
lung cancer in IPF compared with the background
population.
The frequency of depression was 21% in the Danish
cohort, based on registered antidepressant use. A previous
study reported a diagnosis of depression in 11% of IPF pa-
tients [6], while the screening for depression in a mixed ILD
cohort [19,20] revealed clinically relevant depression in
24% of the IPF patients. Depression score was found to be
related to dyspnoea and functional status in the same
cohort. Another study focused on the quality of life of IPF
patients [21] and showed that subjective breathlessness is
related to depressive symptoms and to quality of life, and a
score indicative of significant depression was found in 23.5%
of the patients. It has also been shown that the scores on
the Saint George Respiratory Questionnaire (SGRQ) and the
Hospital Anxiety and Depression Questionnaire are corre-
lated with the severity of IPF based on pulmonary function
parameters [22]. The high frequency of antidepressant
therapy among patients in our cohort suggests that the
recognition of depressive symptoms is coming more into
focus. However, the optimal way to address depressive
symptoms in IPF and the role of physical impairment,
medical therapy and pulmonary rehabilitation needs
further investigation.
Pulmonary hypertension is a serious complication in ILD
and was seen in 21% of our patients; almost half of them
652 C. Hyldgaard et al.had PH at the time of IPF diagnosis. A cross-sectional study
of a mixed ILD population from our centre [23] showed a
prevalence of PH of 14% in all ILDs and 24% in IPF, a prev-
alence level that corroborates our findings. We found no
survival effect of the presence of PH at the time of IPF
diagnosis when adjustment was made for age, gender and
FVC. The number of patients with PH in this cohort was not
large enough to allow stratification based on severity of PH.
The presence of mild PH does not seem to influence sur-
vival, and the number of patients with severe PH in this
study is too low to show a survival difference. Parallel to
our findings, the study by Hamada et al. [16] estimated
pulmonary arterial pressure as part of the initial diagnostic
work up, and showed that the presence of PH provided no
independent prognostic information in a multivariate
regression analysis. In later stages of IPF, PH has been
shown to be an important prognostic determinant [24].
Only one patient was diagnosed with sleep apnoea. The
condition may have been underdiagnosed, but is seeing an
increased focus as overweight is becoming more common in
the Danish population. None of our patients had concomi-
tant COPD based on FEV1/FVC on spirometry. Some pa-
tients had significant emphysema on HRCT-scan, but
radiological emphysema quantification was not performed
systematically.
Patients receiving anticoagulant treatment for clinical
indications had a significantly higher mortality. The impact
of warfarin treatment on IPF outcome when warfarin is
given on clinical indication has only been briefly addressed
in previous studies. The issue of warfarin in IPF has
attracted focus in the light of the recently published results
of the ACE-IPF trial [25] that showed no clinical benefit of
warfarin treatment. The trial was stopped early, because
treatment with warfarin was associated with an increased
risk of mortality in an IPF population who lacked other in-
dications for anticoagulation. The small group of patient on
anticoagulant therapy in our study did not allow stratifi-
cation based on indication for warfarin therapy, and it is
difficult to exclude that the concomitant disease itself may
affect survival. Warfarin treatment as a possible predictor
of survival was investigated in the study of the association
of gastro-oesophageal reflux therapy with survival in IPF
[26]. Four percent of the patients received anticoagulant
treatment, and the association with survival was not sig-
nificant. However, a recent study by Tomassetti et al. [27]
also showed increased mortality in warfarin-treated pa-
tients. Further studies in larger patient cohorts are needed
to address the question of a connection between concom-
itant vitamin K antagonists and disease outcome in IPF.
Whether new oral anticoagulants such as Factor Xa in-
hibitors should be preferred over warfarin for anticoagulant
therapy in patients with IPF is another issue that needs
further investigation.
The role of gastro-oesophageal reflux in IPF is still
debated. In the Danish cohort, PPI treatment was used by
half of the patients as prophylaxis during corticosteroid
treatment or for symptomatic GER, and symptomatic GER
may have been underreported. Previous studies have
demonstrated differences in outcome based on GER medi-
cation use. One study has shown improved survival in pa-
tients treated with PPI [26], but this finding was not
retrieved in our smaller cohort, perhaps because protonpump inhibitor therapy was given prophylactically in many
cases. The study by Lee et al. that was based on patients in
the placebo arms of three clinical trials in IPF [28], showed
a small, but statistically significant difference in FVC
decline at 30 weeks in favour of PPI treatment.
Prognostic models in IPF, such as the GAP score [3] or the
Composite Physiology Index (CPI) [29], focus on factors
directly related to IPF and are strong prognostic de-
terminants. However, none of these models have incorpo-
rated the impact of comorbidities, and the role of
comorbidity in IPF prognosis is still not clear. In COPD, a
newly introduced comorbidity index, the COTE index [30],
identified 12 comorbidities that confer an independent risk
of death in COPD patients and complements the BODE index
[31] in prediction of survival. For each BODE score quartile,
the characterization of patients by the level of COTE score
provides additional prognostic information when added to
the BODE score. This model may inspire the incorporation
of concomitant diseases into prognostic models in IPF.
Our study is limited by its small size and limited number
of patients with comorbidities. However, it provides valu-
able information of the occurrence and impact of common
comorbid conditions in a population-based cohort of IPF
patients.
Conclusion
The present study suggests an increased mortality in di-
abetics and in patients experiencing cardiovascular events
in the course of their fibrotic disease. These findings
emphasize the need of careful diagnosis and treatment of
comorbidities and their risk factors in patients with IPF. In
the absence of efficient treatment options for the majority
of patients diagnosed with IPF, this may play a role in the
effort to optimize the survival of IPF patients. The findings
in this study also suggest that anticoagulant treatment with
vitamin K antagonists may be associated with a more
serious outcome, but further studies of the role of comor-
bidities and concomitant medication in IPF are needed.Conflicts of interest
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